Prevention of Pneumococcal Disease Among Infants and Children --- Use of 13-Valent Pneumococcal Conjugate Vaccine and 23-Valent Pneumococcal Polysaccharide Vaccine
This report, published by the US Centers for Disease Control and Prevention (CDC), summarizes recommendations approved by the CDC's Advisory Committee on Immunization Practices (ACIP) on February 24, 2010, for the use of 13-valent pneumococcal conjugate vaccines (PCVs) to prevent pneumococcal disease in infants and young children less than six years of age. The report also includes recommendations also for the targeted use of the 23-valent pneumococcal polysaccharide vaccine (PPSV23, formerly PPV23) in children aged 2 to 18 years of age with underlying medical conditions that increase their risk for contracting pneumococcal disease or experiencing complications of pneumococcal disease if infected.
Author(s): US Centers for Disease Control and Prevention
Visit web page (English)
(Located at www.cdc.gov)